Stryker reports second quarter 2023 operating results
Pharmaceutical giant Stryker has reported its second quarter net sales growth of $5.2bn (£4.5bн) in the first three months of the year, according to a report from the US financial regulator. Reports have revealed further data.
Source: orthospinenews.comPublished on 2023-08-03
Related news
- Evaluating EFIV Tailwinds | ETF Trends
- ESG in the United States : A complex landscape | Eversheds Sutherland ( US ) LLP
- Developing nations want the rich to pay for climate change
- IGT Reinforces ESG Leadership with Commitment to the Science Based Targets Initiative
- Deutsche Bank DWS to Keep ESG Focus After Greenwashing Claims
- The Herald review of the year 2021
- KPMG outlines ESG watermark ambitions
- Key Insurance Cases and Developments – 2022 In Review | Hinshaw & Culbertson - Insights for Insurers
- Straightforward talking needed to engage staff on ESG | The Lawyer | Legal insight , benchmarking data and jobs
- PROFRAC COMPLETES ACQUISITION OF FTS INTERNATIONAL , ITS RELATED FINANCING TRANSACTIONS AND NAMES NEW CFO
- Ahead of key summit talks , concerns about the precision and scale of World Bank climate finance could erode confidence
- The missing link in plastics circularity
- Brian Wilson : There nothing green about dividing Britain or closing down the North Sea
- Canadian Solar Taps Mesquite for New $250M Solar Module Production Facility
- How Retailers can Overcome the Challenges Faced on the Path to Sustainability